{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:08:33Z","timestamp":1793891313196,"version":"4.8.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02361089"],"award-info":[{"award-number":["RF-2016-02361089"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2014 Id.15584"],"award-info":[{"award-number":["IG 2014 Id.15584"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, characterized by a poor prognosis mainly due to recurrence and therapeutic resistance. It has been widely demonstrated that glioblastoma stem-like cells (GSCs), a subpopulation of tumor cells endowed with stem-like properties is responsible for tumor maintenance and progression. Moreover, it has been demonstrated that GSCs contribute to GBM-associated neovascularization processes, through different mechanisms including the transdifferentiation into GSC-derived endothelial cells (GdECs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In order to identify druggable cancer-related pathways in GBM, we assessed the effect of a selection of 349 compounds on both GSCs and GdECs and we selected elesclomol (STA-4783) as the most effective agent in inducing cell death on both GSC and GdEC lines tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elesclomol has been already described to be a potent oxidative stress inducer. In depth investigation of the molecular mechanisms underlying GSC and GdEC response to elesclomol, confirmed that this compound induces a strong increase in mitochondrial reactive oxygen species (ROS) in both GSCs and GdECs ultimately leading to a non-apoptotic copper-dependent cell death. Moreover, combined in vitro treatment with elesclomol and the alkylating agent temozolomide (TMZ) enhanced the cytotoxicity compared to TMZ alone. Finally, we used our experimental model of mouse brain xenografts to test the combination of elesclomol and TMZ and confirmed their efficacy in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results support further evaluation of therapeutics targeting oxidative stress such as elesclomol with the aim of satisfying the high unmet medical need in the management of GBM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-021-02031-4","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T07:02:49Z","timestamp":1626073369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth"],"prefix":"10.1186","volume":"40","author":[{"given":"Mariachiara","family":"Buccarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quintino Giorgio","family":"D\u2019Alessandris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Matarrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Mollinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cappannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"D\u2019Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Boe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Biffoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-5615","authenticated-orcid":false,"given":"Lucia","family":"Ricci-Vitiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"issue":"1","key":"2031_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathol-011110-130324","volume":"9","author":"TF Cloughesy","year":"2014","unstructured":"Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014;9(1):1\u201325. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130324.","journal-title":"Annu Rev Pathol"},{"issue":"12","key":"2031_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1101\/gad.261982.115","volume":"29","author":"JD Lathia","year":"2015","unstructured":"Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015;29(12):1203\u201317. https:\/\/doi.org\/10.1101\/gad.261982.115.","journal-title":"Genes Dev"},{"issue":"1","key":"2031_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10014-010-0007-z","volume":"28","author":"M Onishi","year":"2011","unstructured":"Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol. 2011;28(1):13\u201324. https:\/\/doi.org\/10.1007\/s10014-010-0007-z.","journal-title":"Brain Tumor Pathol"},{"issue":"11","key":"2031_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrneurol.2009.159","volume":"5","author":"AD Norden","year":"2009","unstructured":"Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol. 2009;5(11):610\u201320. https:\/\/doi.org\/10.1038\/nrneurol.2009.159.","journal-title":"Nat Rev Neurol"},{"issue":"1\u20132","key":"2031_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1023\/A:1026544214667","volume":"19","author":"GL Semenza","year":"2000","unstructured":"Semenza GL. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 2000;19(1\u20132):59\u201365. https:\/\/doi.org\/10.1023\/A:1026544214667.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"2031_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","volume":"11","author":"C Calabrese","year":"2007","unstructured":"Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69\u201382. https:\/\/doi.org\/10.1016\/j.ccr.2006.11.020.","journal-title":"Cancer Cell"},{"issue":"16","key":"2031_CR7","doi-asserted-by":"publisher","first-page":"7843","DOI":"10.1158\/0008-5472.CAN-06-1010","volume":"66","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1010.","journal-title":"Cancer Res"},{"issue":"1","key":"2031_CR8","doi-asserted-by":"publisher","first-page":"1359479","DOI":"10.1080\/20013078.2017.1359479","volume":"6","author":"L Treps","year":"2017","unstructured":"Treps L, Perret R, Edmond S, Ricard D, Gavard J. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J Extracellular Vesicles. 2017;6(1):1359479. https:\/\/doi.org\/10.1080\/20013078.2017.1359479.","journal-title":"J Extracellular Vesicles"},{"issue":"9","key":"2031_CR9","first-page":"3369","volume":"9","author":"YH Zhou","year":"2003","unstructured":"Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003;9(9):3369\u201375.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2031_CR10","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/cncr.23678","volume":"113","author":"JR Flynn","year":"2008","unstructured":"Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008;113(5):1032\u201342. https:\/\/doi.org\/10.1002\/cncr.23678.","journal-title":"Cancer"},{"issue":"3","key":"2031_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1023\/A:1023367223575","volume":"62","author":"A Salmaggi","year":"2003","unstructured":"Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neuro-Oncol. 2003;62(3):297\u2013303. https:\/\/doi.org\/10.1023\/A:1023367223575.","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"2031_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391\u2013400. https:\/\/doi.org\/10.1038\/nrd1381.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"2031_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2009-0121.","journal-title":"Oncologist"},{"issue":"28","key":"2031_CR14","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733\u201340. https:\/\/doi.org\/10.1200\/JCO.2008.19.8721.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2031_CR15","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMc1403303","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Sulman EP, Mehta MP. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(21):2048\u20139. https:\/\/doi.org\/10.1056\/NEJMc1403303.","journal-title":"N Engl J Med"},{"issue":"8","key":"2031_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573.","journal-title":"N Engl J Med"},{"issue":"21","key":"2031_CR17","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMc1403303","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(21):2049. https:\/\/doi.org\/10.1056\/NEJMc1403303.","journal-title":"N Engl J Med"},{"issue":"8","key":"2031_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1308345.","journal-title":"N Engl J Med"},{"issue":"3","key":"2031_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220\u201331. https:\/\/doi.org\/10.1016\/j.ccr.2009.01.027.","journal-title":"Cancer Cell"},{"issue":"3","key":"2031_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/neuonc\/nop027","volume":"12","author":"JF de Groot","year":"2010","unstructured":"de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology. 2010;12(3):233\u201342.","journal-title":"Neuro-oncology"},{"issue":"6","key":"2031_CR21","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/ijc.31983","volume":"144","author":"ML Falchetti","year":"2019","unstructured":"Falchetti ML, D'Alessandris QG, Pacioni S, Buccarelli M, Morgante L, Giannetti S, et al. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1. Int J Cancer. 2019;144(6):1331\u201344. https:\/\/doi.org\/10.1002\/ijc.31983.","journal-title":"Int J Cancer"},{"issue":"7325","key":"2031_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nature09557","volume":"468","author":"L Ricci-Vitiani","year":"2010","unstructured":"Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010;468(7325):824\u20138. https:\/\/doi.org\/10.1038\/nature09557.","journal-title":"Nature"},{"issue":"15","key":"2031_CR23","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1158\/0008-5472.CAN-16-3094","volume":"77","author":"H Yan","year":"2017","unstructured":"Yan H, Romero-Lopez M, Benitez LI, Di K, Frieboes HB, Hughes CCW, et al. 3D mathematical modeling of glioblastoma suggests that transdifferentiated vascular endothelial cells mediate resistance to current standard-of-care therapy. Cancer Res. 2017;77(15):4171\u201384. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3094.","journal-title":"Cancer Res"},{"issue":"9","key":"2031_CR24","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/cdd.2008.72","volume":"15","author":"L Ricci-Vitiani","year":"2008","unstructured":"Ricci-Vitiani L, Pallini R, Larocca LM, Lombardi DG, Signore M, Pierconti F, et al. Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ. 2008;15(9):1491\u20138. https:\/\/doi.org\/10.1038\/cdd.2008.72.","journal-title":"Cell Death Differ"},{"issue":"24","key":"2031_CR25","doi-asserted-by":"publisher","first-page":"8205","DOI":"10.1158\/1078-0432.CCR-08-0644","volume":"14","author":"R Pallini","year":"2008","unstructured":"Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14(24):8205\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0644.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2031_CR26","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/ijc.33370","volume":"148","author":"P Visconti","year":"2021","unstructured":"Visconti P, Parodi F, Parodi B, Casarino L, Romano P, Buccarelli M, et al. Short tandem repeat profiling for the authentication of cancer stem-like cells. Int J Cancer. 2021;148(6):1489\u201398. https:\/\/doi.org\/10.1002\/ijc.33370.","journal-title":"Int J Cancer"},{"issue":"8","key":"2031_CR27","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/neuonc\/now304","volume":"19","author":"QG D'Alessandris","year":"2017","unstructured":"D'Alessandris QG, Biffoni M, Martini M, Runci D, Buccarelli M, Cenci T, et al. The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. Neuro Oncol. 2017;19(8):1097\u2013108. https:\/\/doi.org\/10.1093\/neuonc\/now304.","journal-title":"Neuro Oncol"},{"issue":"28","key":"2031_CR28","doi-asserted-by":"publisher","first-page":"44113","DOI":"10.18632\/oncotarget.9859","volume":"7","author":"M Signore","year":"2016","unstructured":"Signore M, Buccarelli M, Pilozzi E, De Luca G, Cappellari M, Fanciulli M, et al. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget. 2016;7(28):44113\u201328. https:\/\/doi.org\/10.18632\/oncotarget.9859.","journal-title":"Oncotarget"},{"key":"2031_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0065-230X(08)60912-4","volume":"35","author":"MC Berenbaum","year":"1981","unstructured":"Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res. 1981;35:269\u2013335. https:\/\/doi.org\/10.1016\/S0065-230X(08)60912-4.","journal-title":"Adv Cancer Res"},{"issue":"12","key":"2031_CR30","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/neuonc\/noaa127","volume":"22","author":"M Buccarelli","year":"2020","unstructured":"Buccarelli M, Lulli V, Giuliani A, Signore M, Martini M, D'Alessandris QG, et al. Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. Neuro Oncol. 2020;22(12):1771\u201384. https:\/\/doi.org\/10.1093\/neuonc\/noaa127.","journal-title":"Neuro Oncol"},{"issue":"8","key":"2031_CR31","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1074\/jbc.M409752200","volume":"280","author":"P Matarrese","year":"2005","unstructured":"Matarrese P, Tinari A, Mormone E, Bianco GA, Toscano MA, Ascione B, et al. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem. 2005;280(8):6969\u201385. https:\/\/doi.org\/10.1074\/jbc.M409752200.","journal-title":"J Biol Chem"},{"issue":"3","key":"2031_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.nbd.2006.11.005","volume":"25","author":"D Merlo","year":"2007","unstructured":"Merlo D, Mollinari C, Inaba Y, Cardinale A, Rinaldi AM, D'Antuono M, et al. Reduced GABAB receptor subunit expression and paired-pulse depression in a genetic model of absence seizures. Neurobiol Dis. 2007;25(3):631\u201341. https:\/\/doi.org\/10.1016\/j.nbd.2006.11.005.","journal-title":"Neurobiol Dis"},{"issue":"10","key":"2031_CR33","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/cdd.2012.44","volume":"19","author":"CM Tate","year":"2012","unstructured":"Tate CM, Pallini R, Ricci-Vitiani L, Dowless M, Shiyanova T, D'Alessandris GQ, et al. A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death Differ. 2012;19(10):1644\u201354. https:\/\/doi.org\/10.1038\/cdd.2012.44.","journal-title":"Cell Death Differ"},{"key":"2031_CR34","volume-title":"R: a language and environment for statistical computing","author":"Team RC","year":"2013","unstructured":"Team RC: R: a language and environment for statistical computing. 2013."},{"key":"2031_CR35","unstructured":"Allaire J. RStudio: integrated development environment for R, vol. 770. Boston; 2012."},{"key":"2031_CR36","doi-asserted-by":"publisher","unstructured":"Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J: g:profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res 2019, 47(W1):W191-W198, DOI: https:\/\/doi.org\/10.1093\/nar\/gkz369.","DOI":"10.1093\/nar\/gkz369"},{"issue":"D1","key":"2031_CR37","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353\u201361. https:\/\/doi.org\/10.1093\/nar\/gkw1092.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"2031_CR38","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/nar\/gkz401","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47(W1):W199\u2013205. https:\/\/doi.org\/10.1093\/nar\/gkz401.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2031_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2045-824X-3-11","volume":"3","author":"PC Rae","year":"2011","unstructured":"Rae PC, Kelly RD, Egginton S, St John JC. Angiogenic potential of endothelial progenitor cells and embryonic stem cells. Vasc Cell. 2011;3(1):11. https:\/\/doi.org\/10.1186\/2045-824X-3-11.","journal-title":"Vasc Cell"},{"issue":"1","key":"2031_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1006\/phrs.1999.0655","volume":"42","author":"T Bachetti","year":"2000","unstructured":"Bachetti T, Morbidelli L. Endothelial cells in culture: a model for studying vascular functions. Pharmacol Res. 2000;42(1):9\u201319. https:\/\/doi.org\/10.1006\/phrs.1999.0655.","journal-title":"Pharmacol Res"},{"issue":"6","key":"2031_CR41","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/stem.1661","volume":"32","author":"LE Sidney","year":"2014","unstructured":"Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014;32(6):1380\u20139. https:\/\/doi.org\/10.1002\/stem.1661.","journal-title":"Stem Cells"},{"issue":"11","key":"2031_CR42","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1073\/pnas.1016030108","volume":"108","author":"Y Soda","year":"2011","unstructured":"Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A. 2011;108(11):4274\u201380. https:\/\/doi.org\/10.1073\/pnas.1016030108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2031_CR43","doi-asserted-by":"publisher","unstructured":"Modica-Napolitano JS, Bharath LP, Hanlon AJ, Hurley LD. The Anticancer Agent Elesclomol Has Direct Effects on Mitochondrial Bioenergetic Function in Isolated Mammalian Mitochondria. Biomolecules. 2019;9(8). https:\/\/doi.org\/10.3390\/biom9080298.","DOI":"10.3390\/biom9080298"},{"issue":"10","key":"2031_CR44","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.freeradbiomed.2012.03.017","volume":"52","author":"M Nagai","year":"2012","unstructured":"Nagai M, Vo NH, Shin Ogawa L, Chimmanamada D, Inoue T, Chu J, et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med. 2012;52(10):2142\u201350. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2012.03.017.","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"2031_CR45","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","volume":"15","author":"P Tsvetkov","year":"2019","unstructured":"Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019;15(7):681\u20139. https:\/\/doi.org\/10.1038\/s41589-019-0291-9.","journal-title":"Nat Chem Biol"},{"issue":"7757","key":"2031_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569(7757):503\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1186-3.","journal-title":"Nature"},{"issue":"1","key":"2031_CR47","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1038\/s41467-020-17186-5","volume":"11","author":"CP Couturier","year":"2020","unstructured":"Couturier CP, Ayyadhury S, Le PU, Nadaf J, Monlong J, Riva G, et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat Commun. 2020;11(1):3406. https:\/\/doi.org\/10.1038\/s41467-020-17186-5.","journal-title":"Nat Commun"},{"issue":"16","key":"2031_CR48","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-12-1557","volume":"19","author":"Y Piao","year":"2013","unstructured":"Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013;19(16):4392\u2013403. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1557.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2031_CR49","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1016\/j.bmcl.2013.07.032","volume":"23","author":"S Chen","year":"2013","unstructured":"Chen S, Sun L, Koya K, Tatsuta N, Xia Z, Korbut T, et al. Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol. Bioorg Med Chem Lett. 2013;23(18):5070\u20136. https:\/\/doi.org\/10.1016\/j.bmcl.2013.07.032.","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"2031_CR50","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-08-0298","volume":"7","author":"JR Kirshner","year":"2008","unstructured":"Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang M, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther. 2008;7(8):2319\u201327. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0298.","journal-title":"Mol Cancer Ther"},{"issue":"32","key":"2031_CR51","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1200\/JCO.2008.17.1579","volume":"27","author":"S O'Day","year":"2009","unstructured":"O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009;27(32):5452\u20138. https:\/\/doi.org\/10.1200\/JCO.2008.17.1579.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2031_CR52","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1200\/JCO.2012.44.5585","volume":"31","author":"SJ O'Day","year":"2013","unstructured":"O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, et al. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013;31(9):1211\u20138. https:\/\/doi.org\/10.1200\/JCO.2012.44.5585.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2031_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2021.1840550","volume":"30","author":"VM Gohil","year":"2021","unstructured":"Gohil VM. Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders. Expert Opin Investig Drugs. 2021;30(1):1\u20134. https:\/\/doi.org\/10.1080\/13543784.2021.1840550.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"2031_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bcp.2014.12.008","volume":"93","author":"BB Hasinoff","year":"2015","unstructured":"Hasinoff BB, Wu X, Yadav AA, Patel D, Zhang H, Wang DS, et al. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with cu (II). Biochem Pharmacol. 2015;93(3):266\u201376. https:\/\/doi.org\/10.1016\/j.bcp.2014.12.008.","journal-title":"Biochem Pharmacol"},{"issue":"6491","key":"2031_CR55","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1126\/science.aaz8899","volume":"368","author":"LM Guthrie","year":"2020","unstructured":"Guthrie LM, Soma S, Yuan S, Silva A, Zulkifli M, Snavely TC, et al. Elesclomol alleviates Menkes pathology and mortality by escorting cu to cuproenzymes in mice. Science. 2020;368(6491):620\u20135. https:\/\/doi.org\/10.1126\/science.aaz8899.","journal-title":"Science"},{"issue":"3","key":"2031_CR56","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ccr.2006.08.015","volume":"10","author":"PT Schumacker","year":"2006","unstructured":"Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. 2006;10(3):175\u20136. https:\/\/doi.org\/10.1016\/j.ccr.2006.08.015.","journal-title":"Cancer Cell"},{"issue":"1","key":"2031_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-5793(94)01368-B","volume":"358","author":"S Toyokuni","year":"1995","unstructured":"Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995;358(1):1\u20133. https:\/\/doi.org\/10.1016\/0014-5793(94)01368-B.","journal-title":"FEBS Lett"},{"issue":"Pt 6","key":"2031_CR58","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1042\/bst0311441","volume":"31","author":"L Behrend","year":"2003","unstructured":"Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans. 2003;31(Pt 6):1441\u20134. https:\/\/doi.org\/10.1042\/bst0311441.","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"2031_CR59","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-003-0726-5","volume":"53","author":"EO Hileman","year":"2004","unstructured":"Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol. 2004;53(3):209\u201319. https:\/\/doi.org\/10.1007\/s00280-003-0726-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2031_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.drup.2004.01.004","volume":"7","author":"H Pelicano","year":"2004","unstructured":"Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updates. 2004;7(2):97\u2013110. https:\/\/doi.org\/10.1016\/j.drup.2004.01.004.","journal-title":"Drug Resist Updates"},{"key":"2031_CR61","doi-asserted-by":"publisher","first-page":"2428153","DOI":"10.1155\/2016\/2428153","volume":"2016","author":"IG Ryoo","year":"2016","unstructured":"Ryoo IG, Lee SH, Kwak MK. Redox modulating NRF2: a potential mediator of Cancer stem cell resistance. Oxidative Med Cell Longev. 2016;2016:2428153.","journal-title":"Oxidative Med Cell Longev"},{"issue":"11","key":"2031_CR62","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1089\/ars.2012.4529","volume":"16","author":"X Shi","year":"2012","unstructured":"Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal. 2012;16(11):1215\u201328. https:\/\/doi.org\/10.1089\/ars.2012.4529.","journal-title":"Antioxid Redox Signal"},{"issue":"11","key":"2031_CR63","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/jnr.23431","volume":"92","author":"SH Kim","year":"2014","unstructured":"Kim SH, Kwon CH, Nakano I. Detoxification of oxidative stress in glioma stem cells: mechanism, clinical relevance, and therapeutic development. J Neurosci Res. 2014;92(11):1419\u201324. https:\/\/doi.org\/10.1002\/jnr.23431.","journal-title":"J Neurosci Res"},{"issue":"1","key":"2031_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0014-5793(97)01159-9","volume":"416","author":"SS Korshunov","year":"1997","unstructured":"Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 1997;416(1):15\u20138. https:\/\/doi.org\/10.1016\/S0014-5793(97)01159-9.","journal-title":"FEBS Lett"},{"issue":"2","key":"2031_CR65","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.bbamcr.2005.12.012","volume":"1763","author":"A Di Stefano","year":"2006","unstructured":"Di Stefano A, Frosali S, Leonini A, Ettorre A, Priora R, Di Simplicio FC, et al. GSH depletion, protein S-glutathionylation and mitochondrial transmembrane potential hyperpolarization are early events in initiation of cell death induced by a mixture of isothiazolinones in HL60 cells. Biochim Biophys Acta. 2006;1763(2):214\u201325. https:\/\/doi.org\/10.1016\/j.bbamcr.2005.12.012.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"2031_CR66","first-page":"403","volume":"79","author":"S Shuangshoti","year":"1996","unstructured":"Shuangshoti S, Shuangshoti S. Primary diffuse leptomeningeal glioblastoma multiforme of brainstem and spinal cord clinically mimicking meningitis: case report and review of literature. J Med Assoc Thail. 1996;79(6):403\u20138.","journal-title":"J Med Assoc Thail"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-021-02031-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T07:03:58Z","timestamp":1626073438000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-02031-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2031"],"URL":"https:\/\/doi.org\/10.1186\/s13046-021-02031-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}